The program is designed to support pre-clinical and clinical research in the field of Oncology Solid Tumors in Australia, Canada, and Europe. For the 2024 cycle, the program will focus on Breast, Bladder, and Lung cancer. Areas of research may include, but are not limited to:
- Disparities and inequities in cancer care
- Agnostic approaches to target solid tumors
- Combinational drug strategies/approaches to treatment
- Resistance mechanism identification/novel approaches to addressing resistance mechanisms
- Transformative, therapeutic modalities/approaches to treatment
- Patient-specific factors that are predictors of toxicity
- Genomic polymorphisms and impact treatment response
- Novel targets and/or biomarkers/imaging techniques
- Novel diagnostic, prevention, and treatment strategies
- Research to improve Quality of Life (QoL) Patient-Reported Outcomes (PRO's) e.g adverse events, addressing unmet needs for patients
- Any other pre-clinical or clinical research that addresses an unmet medical need or gap in scientific knowledge
Awards granted under the program may not be duplicative of funding from institutional or hospital, other governmental, non-governmental, or industry sources. Applicants seeking an award for research projects that are currently receiving or may receive partial funding from other sources are required to submit appropriate evidence, including budget information related to the other sources, to demonstrate that there is no direct overlap in funding.
Proposals utilising Gilead or Kite product(s) are not eligible for funding through the Research Scholars Program. Proposals involving Gilead or Kite product(s) should be submitted for review under the Investigator-Sponsored Research Grant Program through the ISR online portal.
Proposals are reviewed by an independent Scientific Review Committee, (no Commercial involvement in review or selection, i.e., Marketing, Sales, and Commercial Strategy), and are reviewed based upon the criteria outlined on this website.
The Research Scholars Program is intended to support independent research by emerging investigators that is unrelated to Gilead’s strategies or priorities. However, all research projects selected by the Scientific Review Committee will need to be approved by an internal validation committee that, in rare circumstances, may be unable to support clinical interventional studies that might compromise existing Gilead portfolio evidence e.g., focused solely on the safety and/or efficacy of competitor products, direct comparisons of Gilead products with competitors, etc.
October 2023, IHQ-UNB-4889